Skip to main content
Fig. 5 | BMC Medical Informatics and Decision Making

Fig. 5

From: Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness

Fig. 5

Patient BRCA1/2 mutation status versus PARP inhibitor (“Olaparib”, “Rucaparib”, and “Niraparib”) Prescription. Mut = with BRCA1/2 mutation, VUS = with BRCA1/2 VUS, None = none of the above. “PARPi discussion only” = patients with only discussion or recorded activity related to this drug; “PARPi discussion + prescription” = patients with discussion as well as confirmed prescriptions from UDP, CDM reports and clinical notes “current_medication” section

Back to article page

BMC Medical Informatics and Decision Making

ISSN: 1472-6947

Contact us